Sign In
Buy VCEL
$45.96
-1.65 (-3.47%)
At Close: Jul 31, 2026
Vericel Corporation (VCEL) Q1 2025 Earnings Conference Call Transcript
01:52pm, Thursday, 08'th May 2025
Vericel Corporation. (NASDAQ:VCEL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Eric Burns - VP, Finance and IR Nick Colangelo - CEO Joe Mara - CFO Conference Call Par
Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates
10:05am, Thursday, 08'th May 2025
Vericel Corporation (VCEL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
07:55am, Thursday, 08'th May 2025
Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
08:30am, Wednesday, 07'th May 2025
CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Comp
Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025
08:30am, Thursday, 24'th Apr 2025
CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Co
Vericel: Scalable Growth With Strong Margins
11:56pm, Wednesday, 05'th Mar 2025
Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials inc
Vericel to Present at Multiple Upcoming Investor Conferences
08:30am, Tuesday, 04'th Mar 2025
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Co
Vericel Corporation (VCEL) Q4 2024 Earnings Conference Call Transcript
01:05pm, Thursday, 27'th Feb 2025
Vericel Corporation (NASDAQ:VCEL ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Nick Colangelo - CEO Joe Mara - CFO Eric Burns - VP, Finance and IR Conference Cal
Vericel Corporation (VCEL) Tops Q4 Earnings Estimates
10:05am, Thursday, 27'th Feb 2025
Vericel Corporation (VCEL) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.26 per share a year ago.
Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
07:54am, Thursday, 27'th Feb 2025
Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22%
Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025
08:30am, Thursday, 13'th Feb 2025
CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Com
On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks.
03:09pm, Monday, 03'rd Feb 2025
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Vericel (VCEL) Is a Great Choice for 'Trend' Investors, Here's Why
09:51am, Monday, 03'rd Feb 2025
Vericel (VCEL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our sh
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
08:52am, Wednesday, 15'th Jan 2025
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Wednesday.
Vericel Corporation: Hard To Justify Current Valuation
12:50pm, Thursday, 19'th Dec 2024
Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Core products include MACI, NexoBrid, and Epicel, with Q3 r
